Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

Immunovant (Nasdaq: IMVT) will report financial results for the second quarter ended September 30, 2025 and provide a business update on Monday, November 10, 2025 at 8:00 a.m. ET.

Rhea-AI Summary

Immunovant (Nasdaq: IMVT) will report financial results for the second quarter ended September 30, 2025 and provide a business update on Monday, November 10, 2025 at 8:00 a.m. ET.

The company said investors can access the Roivant (Nasdaq: ROIV) conference call by phone after registering online and can view the presentation and live webcast via the Investors > News & Events section at https://www.immunovant.com/investors/news-events/ir-calendar. An archived webcast will be available on Immunovant’s website after the call.

Argus Oct 28 session

+2.57% close to close Open Argus

Details

News Market Reaction – IMVT

In the Oct 28 session, IMVT gained 2.57%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the second quarter ended September 30, 2025, and provide a business update at 8:00 a.m. ET on Monday, November 10, 2025.

To access the Roivant (Nasdaq: ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under “News & Events” in the Investors section of the Immunovant website at https://www.immunovant.com/investors/news-events/ir-calendar. The archived webcast will be available on Immunovant’s website after the conference call.

About Immunovant
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com.

Contacts:
Investors
Keyur Parekh
keyur.parekh@roivant.com

Media
Stephanie Lee
stephanie.lee@roivant.com

FAQ

When will Immunovant (IMVT) release Q2 2025 financial results and hold its business update?

Immunovant will report results for the quarter ended September 30, 2025 and provide a business update on November 10, 2025 at 8:00 a.m. ET.

How can investors join the Immunovant (IMVT) conference call on November 10, 2025?

Investors can join by phone after registering online via the provided registration link and the company’s IR website.

Where will the Immunovant (IMVT) webcast and presentation be posted?

The live webcast and presentation will be available under Investors > News & Events at https://www.immunovant.com/investors/news-events/ir-calendar.

Will Immunovant (IMVT) make a recording of the November 10, 2025 call available?

Yes, an archived webcast will be posted on Immunovant’s website after the conference call.

Does the announcement mention any earnings figures or guidance for IMVT for Q2 2025?

No, the announcement only schedules the Q2 2025 results release and investor call without providing financial figures or guidance.